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ABSTRACT
Background: To examine survival rates and renal function after partial nephrectomy (PN) and 
radical nephrectomy (RN) in patients with chronic kidney disease (CKD).
Methods: We studied 4,332 patients who underwent PN or RN for pathological T1a-T2N0M0 
renal cell carcinoma from 1988 to 2014. Patients were divided into two subgroups of CKD 
stage I–II and stage III. Kidney function, and survival outcomes were compared between 
groups.
Results: We included 1,756 patients with CKD I–II and 276 patients with CKD III in the final 
pair-matched analysis. Kidney function was significantly better preserved in the PN than in 
the RN group among all patients. However, the beneficial effect of PN on kidney function 
gradually disappeared over time in CKD III patients. The 5-year overall survival (OS) rates 
after PN and RN differed in patients with CKD I–II disease (99.4% vs. 96.5%, respectively, 
P = 0.015). The 5-year OS rates after surgery were not affected by mode of nephrectomy in 
CKD III patients (97.8% vs. 93.5%, P = 0.103). The 5-year cancer-specific survival rates did 
not differ between treatment groups in all CKD stage. Cox hazard analysis showed that the 
operative method was a significant factor for OS in CKD I–II patients (hazard ratio [HR], 
0.320; confidence interval [CI], 0.122–0.840; P = 0.021). However, PN was not beneficial in 
terms of OS in CKD III patients (HR, 0.395; CI, 0.086–1.172; P = 0.117).
Conclusion: PN is associated with a higher OS rate and better kidney function in patients 
with preoperative CKD stage I and II, but not in those with CKD stage III.
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INTRODUCTION
Chronic kidney disease (CKD) is a well-known risk factor for cardiovascular disease and 
mortality.1 CKD caused by nephrectomy may increase mortality by inducing cardiovascular 
disease; thus, to preserve kidney function, partial nephrectomy (PN) has become the 
standard surgical care for small renal masses.2-5 However, the benefits of partial versus 
radical nephrectomy (RN) are still under debate, particularly as they relate to the survival 
advantage of PN.6-15
PN is the preferred treatment modality for renal cell carcinoma (RCC) in patients with pre-
existing CKD, when technically feasible. However, little is known about differences in overall 
survival (OS) and postoperative renal function between patients undergoing RN and PN for 
the treatment of RCC in patients with pre-existing CKD. To address this gap in the literature, 
we evaluated the impact of PN over RN on survival rate and kidney function in patients with 
stage III CKD.
METHODS
Study population
We retrospectively collected data from 5,916 patients who underwent RN or PN for localized 
RCC from January 1988 through December 2014 at eight institutions in Korea.16 After 
excluding 1,584 patients with solitary kidney, bilateral RCC, stage pT3 or greater, lymph node 
or distant metastases, preoperative hemodialysis, or pre-existing stage IV CKD (estimated 
glomerular filtration rate [eGFR] < 30 mL/min/1.73 m2) and those with missing preoperative 
kidney function records, we finally analyzed 4,332 patients who underwent PN or RN for 
pathological T1a-T2N0M0 RCC in this study. To evaluate the effects of PN on survival rate 
according to CKD stage, we divided patients into two subgroups: CKD I–II (eGFR ≥ 60 
mL/min/1.73 m2) and CKD III (30 ≤ eGFR < 60 mL/min/1.73 m2). Data included age, sex, 
body mass index (BMI), preoperative nutritional status (albumin and hemoglobin levels), 
comorbidities (diabetes and hypertension), American Society of Anesthesiologists (ASA) 
score, tumor size, pathologic stage, Fuhrman grade, tumor histology, and preoperative 
kidney function (eGFR).
Primary outcomes
The primary outcome was difference in postoperative kidney function and OS between the 
PN and RN arm according to baseline kidney function. OS was calculated by death from 
any cause after surgery. Cancer-specific survival (CSS) was assessed by the cancer-related 
death rate. Data regarding death and the cause were obtained from the database of every 
participating center and updated by the office for Korean National Statistics. The follow-up 
period was calculated from the date of surgery to the date of the last known contact with 
the patient or the date of death. To assess the longitudinal change in kidney function after 
nephrectomy, serial serum creatinine data were collected annually for each patient. The eGFR 
was calculated using the Modification of Diet in Renal Disease equation.17
Statistical analysis
Differences between groups of patients receiving PN and RN in baseline clinical and 
pathological characteristics were compared using the Mann-Whitney test for continuous 
variables and the χ2 test for categorical variables. To reduce the impact of treatment selection 
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bias, we performed rigorous adjustment for significant differences in characteristics of 
patients by use of the propensity score. Patients were pair-matched by age, sex, BMI, 
preoperative nutritional status (albumin and hemoglobin levels), comorbidities (diabetes and 
hypertension), ASA score, tumor size, pathologic stage, Fuhrman grade, tumor histology, 
and preoperative kidney function (eGFR). OS and CSS were estimated by the Kaplan-Meier 
method and compared by the log-rank test. OS represents the time from surgery to death 
from any cause. CSS represents the time from surgery to death by cancer. Cox proportional 
hazards regression models were used to assess the relation of surgery type with survival rate 
or new onset of stage IV CKD. In the descriptive analyses of kidney function, the mean eGFR 
in each group was evaluated separately and plotted against each follow-up point. Probabilities 
of freedom from new onset of stage IV CKD after nephrectomy were also compared using 
Kaplan-Meier plots. To study the relationship between nephrectomy type and repeated 
longitudinal measurements of eGFR, and to obtain the slope of the kidney function decline 
over time and reliable confidence intervals (CIs) of nephrectomy type effects on the renal 
function trajectory, linear mixed models (with random intercepts and slopes specific to each 
participant) were used. We calculated a separate regression line with time slopes to compare 
the differences in the slopes of eGFR decline according to the nephrectomy type. Two-
sided tests were performed, and P values < 0.05 were considered statistically significant. All 
statistical analyses were conducted using the Statistical Package for the Social Sciences (SPSS 
version 24.0; IBM, Chicago, IL, USA).
Ethics statement
This study was approved by the Institutional Review Board (IRB) of Seoul National University 
Bundang Hospital (B-1202/145-102) and each participating institution.
RESULTS
Patient demographic and clinical characteristics
Table 1 shows the baseline characteristics of patients. Before propensity matching analysis, 
there were significant differences in tumor size, diabetes distribution ratio, Fuhrman grade, 
pathologic stage, and tumor histology type between RN and PN arms. These differences were 
eliminated by matching. In the CKD I–II group, 878 RN patients were matched with 878 PN 
patients. The median pre-eGFRs were 77.1 and 78.7 mL/min/1.73 m2 in each arm (RN vs. PN), 
respectively. The median follow-up durations in the RN and PN arms were 52 (interquartile 
range [IQR], 18–81) and 43 (IQR, 12–62) months, respectively. In the CKD III group, 138 RN 
patients were matched with 138 PN patients. The median pre-eGFRs were 54.1 and 53.8 mL/
min/1.73 m2 in each arm (RN vs. PN), respectively. The median follow-up durations in the RN 
and PN arms were 56 (IQR, 18–78) and 52 (IQR, 20–72) months, respectively.
Kidney function after radical or PN
Among patients with CKD stage I–II, kidney function was significantly better preserved in 
the PN group than in the RN group regardless of the postoperative period (Fig. 1A). Also, PN 
showed better kidney function compared with RN in the early postoperative period among 
patients with CKD stage III. However, the beneficial effect of PN on kidney function was not 
sustained (Fig. 1B). There was a significant difference in the decreasing eGFR between the 
PN and RN groups among patients with CKD stage I–II (−0.039 vs. −0.302 mL/min/1.73 m2/
mon, respectively, P < 0.001; Fig. 2A). However, RN was not associated with a higher eGFR 
decrease compared to PN among patients with stage III CKD (−0.077 vs. −0.073 mL/min/1.73 
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m2/mon, respectively, P = 0.589; Fig. 2B). Kaplan-Meier analysis showed that the 5-year CKD 
IV-free survival rates after surgery were not significantly different among patients with CKD 
stage I–II and stage III. (Fig. 2C and D). The incidences of new onset CKD stage IV after RN 
and PN were 3.6% (five patients) and 1.4% (two patients). However, in Cox hazards models 
for CKD stage IV, patients who underwent PN were not significantly different compared with 
their RN-treated counterparts (hazard ratio [HR], 0.573; 95% CI, 0.137–2.400; P = 0.446). 
Only one patient in the RN arm required dialysis.
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Table 1. Baseline characteristics of patients who underwent PN or RN after propensity score matching
Variables CKD I–II CKD III
RN PN P value RN PN P value
No. of patients 878 878 138 138
Age, yr 54 (45–63) 54 (45–62) 0.753 66 (55–71) 65 (56–71) 0.878
BMI, kg/m2 24.2 (22.2–26.4) 24.3 (22.2–26.4) 0.119 24.8 (23.1–26.8) 24.7 (22.8–26.6) 0.535
Sex 0.715 0.097
Male 612 (69.7) 619 (70.5) 99 (71.7) 85 (61.6)
Female 266 (30.3) 259 (29.5) 39 (28.3) 53 (38.4)
Diabetes 0.471 0.778
No 773 (88.0) 763 (86.9) 106 (76.8) 104 (75.4)
Yes 105 (12.0) 115 (13.1) 32 (23.2) 34 (24.6)
Hypertension 0.505 0.715
No 606 (69.0) 593 (67.5) 57 (41.3) 60 (43.5)
Yes 272 (31.0) 285 (32.5) 81 (58.7) 78 (56.5)
Tumor size, mm 32.0 (25.0–40.0) 33.0 (25.0–40.0) 0.892 30.0 (22.0–36.5) 30.0 (22.0–36.5) 0.938
ASA score 0.774 0.483
1 427 (48.6) 413 (47.0) 37 (26.8) 42 (30.4)
2 42.4 (48.3) 439 (50.0) 87 (63.0) 77 (55.8)
3 27 (3.1) 26 (3.0) 12 (8.7) 18 (13.0)
4 0 (0.0) 0 (0.0) 2 (1.4) 1 (0.7)
Fuhrman grade 0.841 0.895
Grade I 85 (9.7) 81 (9.2) 19 (6.5) 7 (5.1)
Grade II 420 (47.8) 406 (46.2) 78 (56.5) 80 (58.0)
Grade III 256 (29.2) 272 (31.0) 45 (32.6) 43 (31.2)
Grade IV 117 (13.3) 119 (13.6) 6 (4.3) 8 (5.8)
Pre-creatinine, mg/dL 0.90 (0.8–1.08) 0.92 (0.8–1.09) 0.129 1.30 (1.20–1.46) 1.30 (1.10–1.40) 0.135
Pre-eGFR, mL/min/1.73 m2 77.1 (69.3–87.9) 78.7 (69.5–88.9) 0.574 54.1 (48.3–57.1) 53.8 (48.3–56.6) 0.593
Albumin, g/dL 4.2 (4.0–4.5) 4.3 (4.1–4.5) 0.251 4.2 (3.7–4.4) 4.3 (4.0–4.5) 0.263
Hemoglobin, g/dL 14.0 (12.8–15.1) 14.2 (13.1–15.3) 0.142 13.6 (12.1–14.7) 13.4 (12.1–14.8) 0.484
Estimated blood loss, mL 195 (90–380) 200 (100–300) 0.299 200 (100–340) 200 (100–350) 0.197
Blood transfusion 0.022 0.496
No 837 (95.3) 855 (97.4) 126 (91.3) 129 (93.5)
Yes 41 (4.7) 23 (2.6) 12 (8.7) 9 (6.5)
POD #1 hemoglobin, g/dL 12.5 (11.3–13.5) 12.7 (11.4–13.6) 0.073 12.2 (11.0–13.2) 12.0 (10.9–12.8) 0.354
Pathologic stage 0.873 0.255
PT1a 673 (76.7) 677 (77.1) 112 (81.2) 116 (84.1)
PT1b 186 (21.2) 185 (21.1) 21 (15.2) 21 (15.2)
PT2 19 (2.2) 16 (1.8) 5 (3.6) 1 (0.7)
Tumor histology 0.425 0.745
Clear cell 774 (88.1) 780 (88.8) 118 (85.5) 115 (83.3)
Papillary 27 (3.1) 16 (1.9) 4 (2.9) 3 (2.2)
Chomophobe 50 (5.7) 57 (6.5) 8 (5.8) 7 (5.0)
Collecting duct 4 (0.5) 2 (0.2) 3 (2.2) 2 (1.5)
Unclassified 5 (0.6) 8 (0.9) 1 (0.7) 2 (1.5)
Other histology 18 (2.0) 15 (1.7) 4 (2.9) 9 (6.5)
Values are presented as number of patients (%) or median (IQR).
RN = redical nephrectomy, PN = partial nephrectomy, CKD = chronic kidney disease, IQR = interquartile range, BMI = body mass index, ASA = American Society of 
Anesthesiologists, POD = postoperative day, eGFR = estimated glomerular filtration rate.
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Patients at risk
PN 878 481 546 402 319 269 201 150
RN 878 475 704 586 557 425 317 238
Patients at risk
PN 138 72 80 94 69 57 51 48
RN 138 75 83 93 71 65 58 53
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Fig. 1. Changes in eGFR over time after RN and PN. (A) Patients with CKD I–II and (B) patients with CKD III. 
eGFR = estimated glomerular filtration rate, RN = radical nephrectomy, PN = partial nephrectomy, CKD = chronic kidney disease.
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Fig. 2. Changes in the eGFR over time after PN (red line) and RN (blue line) stratified by CKD stage (A, B). Slopes are based on regression coefficients from the 
linear mixed models. Solid line: regression line, dotted line: 95% CI. (A) Patients with CKD I–II. (B) Patients with CKD III. Kaplan-Meier survival curves for CKD IV 
free survival stratified by nephrectomy type (C, D). (C) Patients with CKD I–II. (D) Patients with CKD III. Red line: PN; Blue line: RN. 
eGFR = estimated glomerular filtration rate, CKD = chronic kidney disease, PN = partial nephrectomy, RN = radical nephrectomy, CI = confidence interval.
Survival rate after radical or PN
In the CKD I–II group, the 5-year OS rates after surgery were 99.4% for PN versus 96.5% 
for RN (P = 0.015; Fig. 3A). The 5-year CSS rates were 99.7% for PN versus 99.5% for RN 
(P = 0.492; Fig. 3C). Table 2 summarizes the adjusted HRs for clinical end points in the PN 
arm versus the RN arm. Patients undergoing PN were at a significantly lower risk of kidney 
function decrease and death from any cause. In Cox hazards models for OS and CSS, although 
patients who underwent PN did not have a significantly different CSS rate compared with their 
RN-treated counterparts, the OS rate was different (OS: HR, 0.320; 95% CI, 0.122–0.840;  
P = 0.021; CSS: HR, 0.466; 95% CI, 0.050–4.311; P = 0.501). In the CKD III group, the 5-year 
OS rates after surgery were 97.8% for PN versus 93.5% for RN (P = 0.103; Fig. 3B). The 5-year 
CSS rates were 99.3% for PN versus 98.5% for RN (P = 0.287; Fig. 3D). OS and CSS were not 
significantly different between the two arms (OS: HR, 0.395; 95% CI, 0.124–1.260; P = 0.117; 
CSS: HR, 0.313; 95% CI, 0.033–3.008, respectively, P = 0.314).
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Fig. 3. Survival rate stratified by CKD stage and nephrectomy type. Kaplan-Meier estimating curves for overall survival (A, B), and cancer specific survival (C, D) 
according to nephrectomy type (PN [red line] versus RN [blue line]). CKD I–II patients: (A) and (C); CKD III patients: (B) and (D). 
PN = partial nephrectomy, RN = radical nephrectomy, CKD = chronic kidney disease.
DISCUSSION
The effects of PN and RN on survival rate and renal function in patients with stage III CKD 
have not been evaluated in detail. Compared to RN, PN is thought to have a more favorable 
effect on OS in patients with deteriorated preoperative kidney function. In our previous 
study, we observed that the renal function of patients with CKD stage I or II recovered after 
RN and that the same phenomenon occurred in patients with CKD III.18 However, the level of 
renal function recovery was lower in patients with CKD stage III than in those with CKD stage 
I or II. We hypothesized that among patients with CKD III, RN would be more detrimental to 
kidney function than PN, and expected to see a greater survival benefit following PN among 
patients with CKD III than among those with CKD I or II. However, the results of this study 
contradicts our hypothesis.
The major findings of this study were: 1) there was no difference between PN and RN arms in 
the rate of eGFR decrease among CKD stage III patients, although the superior benefit of PN 
over RN was consistently maintained between the two nephrectomy types in CKD stage I–II 
patients; 2) the 5-year OS and CSS survival rates in the RN arm were comparable to those of 
the PN arm in patients with pre-existing CKD III; and 3) the OS was higher after PN than after 
RN in patients with preoperative normal kidney function. The results obtained for CKD stage 
III patients are seemingly counterintuitive because it is conceivable that in pre-existing CKD, 
the functional recovery capacity is not maintained by physiological compensation.
Several underlying mechanisms may explain this phenomenon. First, a similar kidney 
function after nephrectomy may affect the OS rate. After surgery, kidney function was 
significantly better preserved in the PN arm than in the RN arm in the early period after 
surgery. The eGFR drops sharply by 20 mL/min/1.73 m2 on average when RN is performed 
in CKD I–II patients, whereas it decreases by approximately 10 mL/min/1.73 m2 on average 
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Table 2. Cox regression analyses for OS, CSS, and new onset of CKD IV survival
Parameters Propensity score matched cohort
HR 95% CI P value
(A) CKD I–II
OS
PN 0.320 0.122–0.840 0.021
RN (Ref) -
CSS
PN 0.466 0.050–4.311 0.501
RN (Ref) -
New onset CKD IV free survival
PN 0.445 0.049–4.045 0.472
RN (Ref) -
(B) CKD III
OS
PN 0.395 0.124–1.260 0.117
RN (Ref) -
CSS
PN 0.313 0.033–3.008 0.314
RN (Ref) -
New onset CKD IV free survival
PN 0.573 0.137–2.400 0.446
RN (Ref) -
OS = overall survival, CSS = cancer-specific survival, CKD = chronic kidney disease, HR = hazard ratio, CI = confidence 
interval, PN = partial nephrectomy, RN = radical nephrectomy.
in CKD III patients. In the CKD III group, patients who underwent PN maintained their 
postoperative kidney function up to a certain level while the postoperative kidney function of 
patients that underwent RN recovered gradually over time; therefore, statistically significant 
differences in the postoperative eGFR of PN and RN groups disappeared with time. Kidney 
ischemia in PN may have irreparable damage to operated kidney in CKD III patients. These 
changes may be associated with the survival rate of patients. Furthermore, it is possible 
that RN may not affect survival unless the eGFR reaches the cutoff value for dialysis (30 mL/
min/1.73 m2), a variable which did not differ between groups.
Second, PN may not increase OS compared to RN in certain patients. Recent studies reported 
that the benefits of PN with regard to OS or kidney function can vary depending on the patient's 
preoperative kidney function, age, comorbidity, and tumor size and anatomy.19-24 Woldu et al.19 
found that the benefits of PN on kidney function were observed only in patients with CKD stage 
II, and not in those with CKD stage III, despite the fact that most urologists would prioritize 
PN in the latter group in daily clinical practice. Sun et al.20 reported that compared to RN, PN 
was not protective of other-cause mortality in elderly patients (aged ≥ 75) with localized RCC or 
those with multiple comorbidities at diagnosis. Meanwhile, Larcher et al.21 argued that PN was 
beneficial only to patients with significant comorbidities. However, the authors also contended 
that PN decreased other cause mortality over RN only in specific subgroup of patients with 
RCC. An et al.22 and Chung et al.23 also reported that PN was not more favorable than RN in 
terms of OS in elderly patients. Kopp et al.24 compared survival differences to investigate the 
prognostic impact of tumor anatomical variation or stage, and found that the benefits of PN 
might fade away for complex tumors. Another study also confirmed no survival difference 
between PN and RN in a propensity adjusted cohort of patients with T1b RCC.25 The current 
study demonstrated that the differences between OS rates after PN and RN disappeared in 
patients with pre-existing CKD.
We found that the relative benefit of PN over RN in reducing mortality and preserving 
kidney function was consistently observed in patients with preoperatively normal kidney 
function. Furthermore, given that the kidney function and survival outcomes were 
comparable for the two nephrectomy types, RN may be selected as a relatively safe treatment 
for RCC in specific patients with pre-existing CKD stage III. The remarkable finding in this 
study is that the benefits following PN were not sustained in patients with pre-existing 
CKD stage III. However, given the significant risks associated with RN, PN should still be 
the method of choice in this patient group. Also, it should not be overinterpreted that RN 
would not completely cause severe cardiovascular disease or fatal mortality in patients with 
preexisting CKD.
Our study has several limitations. First, this was a retrospective study, and this design 
may have affected the results owing to unmeasured confounders. No statistical method of 
adjustment can completely abolish this limitation. Second, only a small number of patients 
were followed up. It is possible that the lack of difference in OS between the two arms in stage 
III CKD may have been affected by the limited number of patients throughout follow-up. 
Third, only healthy patients with available contact information and relatively better baseline 
kidney function (CKD IIIA) who were still alive were included as CKD stage III patients.
The choice of PN versus RN should be made based on a variety of clinical factors. When 
considering PN in a patient with pre-existing CKD, the issue of potential morbidity in 
relation to the patient's health condition needs to be discussed, because the decision to 
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perform RN versus PN is influenced by preoperative renal function. Our study adds to the 
current knowledge about the beneficial effect of PN on survival rate and kidney function in 
patients with pre-existing CKD. Our use of a large consecutive patients recruited at multiple 
centers may be a good reference indicator of real world outcomes.
In conclusion, PN is associated with a higher OS rate in patients with preoperative CKD 
stages I and II. However, compared with RN, PN did not show a better 5-year risk of death 
and kidney function in patients with pre-existing CKD stage III. Additional studies should 
be conducted to investigate the patient characteristics for which the benefit of PN may be 
maximized.
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